POMPANO BEACH, Fla., April 01, 2025 (GLOBE NEWSWIRE) — BioStem Applied sciences, Inc. BSEM, a number one MedTech firm specializing within the improvement, manufacturing, and commercialization of placental-derived merchandise for superior wound care, proclaims it has filed for an extension to submit its annual report for the 12 months ended December 31, 2024 to the OTC
The corporate is at present present process a compulsory Securities Alternate Fee (SEC) assessment course of associated to its Kind 10 registration assertion, which can affect the monetary statements or disclosures within the annual report. Administration anticipates submitting the annual report by April 15, which is the expiration of the extension interval.
Jason Matuszewski, Chief Government Officer of BioStem, said:
“We admire our shareholders’ persistence as we navigate the ultimate remark assessment course of for our Kind 10 with the SEC, a needed step to finalize our monetary reporting and full our uplisting to Nasdaq. Upon completion of this course of, we are going to announce the date of our webcast protecting fourth quarter and year-end 2024 outcomes.”
Be a part of BioStem’s Distribution Checklist & Social Media:
To comply with the most recent developments at BioStem, sign-up to the Firm’s e-mail distribution record HERE, and comply with us on X and LinkedIn.
About BioStem Applied sciences, Inc. BSEM:
BioStem Applied sciences is a number one innovator targeted on harnessing the pure properties of perinatal tissue within the improvement, manufacture, and commercialization of allografts. The Firm is concentrated on manufacturing merchandise that change lives, leveraging its proprietary BioREtain® processing methodology. BioREtain® has been developed by making use of the most recent analysis in superior wound care, targeted on sustaining development elements and preserving tissue construction. BioStem Applied sciences’ high quality administration system and customary working procedures have been reviewed and accredited by the American Affiliation of Tissue Banks (“AATB”). These methods and procedures are established per present Good Tissue Practices (“cGTP”) and present Good Manufacturing Processes (“cGMP”). Our portfolio of high quality manufacturers contains AmnioWrap2 ™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Every BioStem Applied sciences placental allograft is processed on the Firm’s FDA registered and AATB accredited web site in Pompano Seashore, Florida.
For extra data go to biostemtechnologies.com and comply with us on X and LinkedIn.
Ahead-Wanting Statements:
Aside from statements of historic reality, this launch additionally comprises forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995 together with with respect to the anticipated submitting of the annual report and conclusion of the SEC assessment course of. These forward-looking statements relate to expectations or forecasts of future occasions. Ahead-looking statements could also be recognized utilizing phrases corresponding to “forecast,” “intend,” “search,” “goal,” “anticipate,” “imagine,” “count on,” “estimate,” “plan,” “outlook,” and “venture” and different comparable expressions that predict or point out future occasions or developments or that aren’t statements of historic issues. Ahead-looking statements with respect to the operations of the Firm, methods, prospects and different elements of the enterprise of the Firm are primarily based on present expectations which can be topic to recognized and unknown dangers and uncertainties, which might trigger precise outcomes or outcomes to vary materially from expectations expressed or implied by such forward-looking statements. These elements embrace, however aren’t restricted to: (1) the affect of any adjustments to the reimbursement ranges for the Firm’s merchandise; (2) the Firm faces vital and persevering with competitors, which might adversely have an effect on its enterprise, outcomes of operations and monetary situation; (3) speedy technological change might trigger the Firm’s merchandise to develop into out of date and if the Firm doesn’t improve its product choices via its analysis and improvement efforts, it could be unable to successfully compete;(4) to be commercially profitable, the Firm should persuade physicians that its merchandise are secure and efficient alternate options to current therapies and that its merchandise must be used of their procedures; (5) the Firm’s potential to boost funds to develop its enterprise; (6) the Firm has incurred vital losses since inception and will incur losses sooner or later; (7) adjustments in relevant legal guidelines or laws; (8) the chance that the Firm could also be adversely affected by different financial, enterprise, and/or aggressive elements; (9) the Firm’s potential to keep up manufacturing of its merchandise in enough portions to fulfill demand; and (10) the COVID-19 pandemic and its affect, if any, on the Firm’s fiscal situation and outcomes of operations; You might be cautioned to not place undue reliance upon any forward-looking statements, which converse solely as of the date made. Though it could voluntarily achieve this every so often, the Firm undertakes no dedication to replace or revise the forward-looking statements, whether or not because of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines.
BioStem Applied sciences, Inc.
Telephone: 954-380-8342
Web site: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Fb: BioStemTechnologies
PCG Advisory
Adam Holdsworth
Telephone: 917-497-9287
E mail: adam@pcgadvisory.com
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
